Full Text View
Tabular View
No Study Results Posted
Related Studies
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
This study is currently recruiting participants.
Study NCT00710970   Information provided by Baylor College of Medicine
First Received: July 7, 2008   Last Updated: September 22, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Urinary Bladder Neoplasms
Additional conditions recognized in this trial
Carcinoma, Transitional Cell
Neoplasms
More general conditions related to this trial
Carcinoma
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
Tamoxifen
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Bone Density Conservation Agents
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Therapeutic Uses
Sponsors listed in this trial
Baylor College of Medicine
AstraZeneca
Cytogen Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services